|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The median size of the tumor was 2 cm, the majority of the patients (66.7%) had moderate breast size (cup B) and the median distance of the tumor from NAC was 7 cm.
|
31448485 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both IDO expression in tumor and serum activity were associated with clinical tumor stage, node stage and estrogen receptor (ER) status (all P < 0.05); clinical response and pathologic complete response (pCR) to NAC were both related to IDO expression and activity prior NAC (all P < 0.05).
|
31844921 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The overall accuracy of MRI in predicting tumor size was not affected by NAC; however, it tends to underestimate tumor size after NAC, especially in patients with T3 lesions and above.
|
31600220 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NAC-CCRT) is an alternative strategy for decreasing tumor size and controlling micrometastases before main treatment.
|
29587665 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All patients with esophageal cancer staged before NAC with PET/CT and after with CT or PET/CT and undergoing resection from 2006 to 2014 were identified. pTR was defined as Mandard tumor regression grade 1-3; imaging parameters included metrics of tumor avidity (SUV<sub>max/mean/peak</sub>), composites of avidity and volume (including metabolic tumor volume), nodal SUV<sub>max</sub>, and our new concepts of mN stage and mNR.
|
27635027 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup analyses of clinical data (serum albumin, cT, cN, cstage and tumor location) were conducted with Cox proportional hazards regression models for patients assigned to receive NAC-S in JCOG9907 and patients in JCOG9906.
|
28334858 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We performed gene expression profiling on pre-NAC+H tumor samples from responding (no or minimal residual disease at surgery) and non-responding patients.
|
27090210 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When dichotomized into high and low TUBB3 expression, discordance between diagnostic biopsies and resection specimens of the primary tumors occurred in 22 % and 40 % in the OP-group and NAC-group, respectively (p = 0.169).
|
24220933 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After NAC, 23.4% (29 of 124) of tumors showed downregulated HER2/neu expression by IHC.
|
23103368 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, pretreatment with NAC, a precursor of intracellular GSH, effectively abrogated gelomulide K-induced caspase-independent cell death and autophagy, suggesting that ROS-mediated downstream signaling is essential to the anticancer effects of gelomulide K. Additionally, in a xenograft model, gelomulide K induced PARP-1 activation and reduced tumor growth.
|
21641992 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that growth-stimulated cells with an elevated basal AP-1 activity, i.e., A549 cells transfected with wild-type c-jun or treated with a tumor promoter, were more sensitive to PEITC-NAC-mediated apoptosis.
|
16166335 |
2005 |